In March, Neuralstem received issuance of EP Patent # 1576134, Method for Discovering Neurogenic Agents, which is part of the small molecule IP, and granted in ten European countries: Belgium, Switzerland, Germany, France, United Kingdom, Ireland, Luxembourg, Netherlands and Sweden, for a total of 11 European patents.
In March, Neuralstem President and CEO Richard Garr was named the 15th most influential person in the stem field in Terrapinn's Total BioPharma's "Top 50 Global Stem Cell Influencers."
In March, Neuralstem secured $8 million in debt financing with Hercules Technology Growth Capital to fund the company's capital budget through late 2014.
In April, Neuralstem received FDA approval to commence the NSI-566 Phase II trial, for ALS, following the excellent safety and tolerability demonstrated in Phase I. The Phase II dose escalation and safety trial to determine the maximum safe tolerated dose will expand to two centers, Emory University Hospital in Atlanta, Georgia, where Phase I was recently completed, and ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, subject to approval by the Institutional Review Board at each institution. The NSI-566/ALS Phase II trial is designed to treat up to 15 ambulatory ALS patients, in five different dosing cohor
|SOURCE Neuralstem, Inc.|
Copyright©2012 PR Newswire.
All rights reserved